Elotuzumab (Empliciti) is a monoclonal antibody that targets signaling lymphocytic activation molecule F7 (SLAMF7), a protein that is highly expressed on the surface of myeloma cells and natural killer cells. The gene discussed is SLAMF7; the disease is plasma cell myeloma.